CNBC’s Jim Cramer delivers his daily Mad Dash.

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

The FDA is fast-tracking Regeneron's planned drug facility in Saratoga County through a new federal pilot program. The ...

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...

As climate change brings longer droughts, more frequent heat waves and increasingly unpredictable growing conditions to ...

Marie Washburn Marie Washburn, Longeveron CFO Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Zion Market Research has published a new research report titled 'Generative AI in Healthcare Market By Component (Solutions and Services), By Function (Medical Imaging & Diagnostics, Drug Discovery & ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies ...

The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure stocks that have driven much of the market’s recent performance. The firm ...